FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
175 letters match. Newest first.
-
DrugsFoshan Yiying Hygiene Products Co., Ltd.
Foshan Yiying, a Chinese OTC drug maker, lacked finished-product testing, stability data and process validation; FDA has blocked its imports.
High risk -
DrugsCreative Essences, Inc.
FDA warns Creative Essences over OTC drug manufacturing failures and an unapproved antiseptic.
High risk -
DrugsColumbia Cosmetics Manufacturing Inc.
Columbia Cosmetics Manufacturing Inc. made OTC sunscreen drugs without adequate current good manufacturing practice, including failed out-of-specification investigations and untested high-risk ingredients.
High risk -
DrugsGussyup LLC dba Private Label Grooming
FDA found Gussyup LLC, a Henderson, Nevada OTC drug maker, lacking quality oversight and ingredient identity testing; company stopped drug production.
High risk -
DrugsMedical Chemical Corporation
FDA warned Medical Chemical Corp over manufacturing violations, unapproved Tincture Green Soap, and improper drug listing.
High risk -
DrugsNature’s Fusions LLC
FDA cited Nature's Fusions for over-the-counter hand sanitizer manufacturing with inadequate stability, component and finished-product testing, and water controls.
High risk -
DrugsLibby Laboratories, Inc.
FDA warned Libby Laboratories of Berkeley, California, that its drug manufacturing violated CGMP, including releasing a hospital antiseptic without microbial testing.
High risk -
AnimalLystn LLC dba Answers Pet Food
FDA warned Answers Pet Food that its raw pet food contained Salmonella and Listeria and was made under insanitary conditions.
High risk -
DrugsDynamic Blending Specialists, Inc.
FDA cited Dynamic Blending Specialists for manufacturing failures in OTC drugs and an unapproved, misbranded oral antiseptic.
High risk -
DrugsHealwell Homeo Private Limited
FDA warns Healwell Homeo over pest-infested drug storage and manufacturing violations.
High risk -
DrugsAmish Origins Management, LLC
FDA warned Amish Origins over manufacturing quality failures and unapproved or misbranded OTC pain relief and lip balm products.
High risk -
DrugsProduct Society LLC
FDA says Product Society LLC, an OTC drugmaker in North Hollywood, California, skipped identity testing for toxic DEG/EG and process validation.
High risk -
DrugsWuxi Medical Instrument Factory Co., Ltd.
FDA warns Wuxi Medical Instrument Factory over insanitary conditions and manufacturing failures for sterile drugs.
High risk -
DrugsNWL Netherlands Services B.V.
FDA cites NWL Netherlands drug plant for inadequate microbial investigations, missing component identity testing, and weak lab data controls.
High risk -
DrugsMentha & Allied Products Private Ltd.
FDA warns Mentha & Allied Products of CGMP failures that leave its APIs adulterated.
High risk -
DrugsBioAsia Worldwide Sdn Bhd
FDA warned BioAsia Worldwide over current good manufacturing practice violations for OTC drugs.
High risk -
DrugsDyno Manufacturing, Inc.
Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.
High risk -
DrugsBEO Pharma Inc. dba BEO Pharmaceuticals Inc.
FDA cited BEO Pharma for manufacturing quality violations, including missing identity testing of high-risk drug ingredients and releasing a batch before microbial testing.
High risk -
DrugsYangzhou Sion Commodity Co., Ltd.
FDA warned Yangzhou Sion Commodity over drug manufacturing failures, including untested high-risk ingredients and unreliable lab records.
High risk -
DrugsRite-Kem Incorporated
FDA warned Rite-Kem over inadequate current good manufacturing practice testing of over-the-counter drugs, including hand sanitizers and antimicrobial products.
High risk -
DrugsVegewax Candleworx Ltd.
FDA warns Vegewax Candleworx over CGMP violations in OTC drug manufacturing, including inadequate component testing and OOS investigations.
High risk -
DrugsAmWiner & Raphe Holdings, LLC dba rapheGenerics Corp
FDA cited rapheGenerics for manufacturing-quality failures and unapproved minoxidil hair regrowth drugs.
High risk -
DrugsChengdu Innovation Pharmaceutical Co., Ltd.
FDA warned Chengdu Innovation Pharmaceutical over CGMP (manufacturing quality rules) failures in API (drug ingredient) manufacturing, including no identity testing of incoming materials.
High risk -
DrugsShantou Kangjie Daily Chemical Industry Co., Ltd
FDA warns Shantou Kangjie over CGMP failures for OTC drugs, including untested ethanol and no quality unit.
High risk -
DrugsImperial Palace Commodity -Dongguan- Co., Ltd.
FDA warns Chinese maker of OTC alcohol wipes that weak component testing and process validation make its drugs adulterated.
High risk -
FoodGuangzhou Sinocon Food Co., Ltd
FDA warns Guangzhou Sinocon Food over food-safety violations in ready-to-eat Oat Beta Glucan powder, including pathogen hazards and inaccurate test certificates.
High risk -
DrugsBhargava Phytolab Private Limited
FDA warns Bhargava Phytolab over drug and API current good manufacturing practice (CGMP) violations, including inadequate testing and sterility controls.
High risk -
DrugsSombra Cosmetics, Inc.
FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.
High risk -
DrugsDr. Brite, LLC
FDA cited Dr. Brite for manufacturing quality failures and selling unapproved, misbranded oral care and hand sanitizer drugs.
High risk -
DrugsLCC Ltd.
FDA warned LCC Ltd. over manufacturing-quality failures, contamination testing gaps, discarded lab data, and unapproved mouthwash drugs.
High risk -
DrugsZhejiang Uniquality Nursing Products Technology Co., Ltd. dba ZheJiang YouQuan Care Products Technology Co., Ltd.
FDA warns Zhejiang Uniquality over inadequate OTC drug component testing and quality oversight; import alert issued.
High risk -
DrugsEurosirel S.P.A
FDA warns Eurosirel over CGMP failures in topical drugs and pain patches, including missing glycerin identity testing.
High risk -
DrugsOriginitalia SRL
FDA warns Originitalia SRL over manufacturing quality failures in OTC drugs, including untested active ingredient and missing release testing.
High risk -
DrugsMultaler et Cie SAS
FDA cites Multaler et Cie for manufacturing failures and unapproved sunscreen after April 2024 inspection.
High risk -
DrugsDiora Kimya Sanayi ve Ticaret Limited Sirketi
FDA cited Diora Kimya for drug manufacturing quality failures and for an unlisted antibacterial soap.
High risk -
DrugsLittle Moon Essentials, LLC
FDA warns Little Moon Essentials over CGMP failures and unapproved topical analgesic drugs made in Dania Beach, Florida.
High risk -
FoodFar East Summit LLC
FDA says Far East Summit sold herbal supplements as unapproved drugs and made them under serious manufacturing violations.
High risk -
DrugsDiamond Chemical Co., Inc.
Diamond Chemical Co. in East Rutherford, NJ, made OTC hand sanitizers without required ingredient and finished-product testing or process validation.
High risk -
DrugsClean Solutions LLC
FDA warned Clean Solutions LLC that its OTC hand soaps and sanitizer were adulterated because it released drugs without component or finished-product testing.
High risk -
DrugsAerosol and Liquid Packaging, Inc.
FDA warns Aerosol and Liquid Packaging on CGMP failures and unapproved antiseptic spray claims.
High risk -
DrugsGreco Gas, Inc.
Greco Gas, Inc. released medical gases without identity or purity testing and without quality oversight.
High risk -
DrugsOrean Personal Care Ltd.
FDA warned Orean Personal Care Ltd. that repeat manufacturing failures make its OTC drugs adulterated.
High risk -
DrugsKaylaan LLC
FDA warns Kaylaan LLC that its fluoride toothpaste tablets were made without release testing, raw material identity testing, and adequate CGMP controls.
High risk -
DrugsIntercos Europe S.p.A
FDA warned Intercos Europe S.p.A over current good manufacturing practice violations in OTC sunscreen drugs, including missing glycerin DEG/EG testing and poor investigations.
High risk -
DrugsGenuine Virgin Aloe Corp dba Triderma
FDA warned Triderma, an Anaheim OTC skin cream maker, of CGMP violations after a January 2024 inspection.
High risk -
DrugsMax Chemical Inc.
FDA warned Max Chemical Inc. in San Juan, Puerto Rico, that its OTC drug manufacturing violated CGMP, making its drugs adulterated.
High risk -
DrugsARG Laboratories, Inc.
FDA found ARG Laboratories released failing over-the-counter drug lots, lacked manufacturing controls, and marketed two unapproved pain creams.
High risk -
DrugsreBom Co., Ltd.
reBom failed current good manufacturing practice for OTC drugs, including inadequate stability and component testing.
High risk -
DrugsSani-Care Salon Products, Inc.
FDA warns Sani-Care Salon Products over CGMP failures in hand sanitizer manufacturing, including inadequate quality oversight and testing.
High risk -
DrugsFancystage Unipessoal, LDA
FDA warned Portugal OTC drug maker Fancystage Unipessoal of repeated CGMP failures, untested ingredients, unvalidated processes and misbranded fluoride mouthwash.
High risk